AU Patent

AU2011244932B9 — New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders

Assigned to Bayer Pharmaceuticals Corp · Expires 2014-06-12 · 12y expired

What this patent protects

Patent listed against chembl-chembl1946170.

Drugs covered by this patent

chembl-chembl1946170 (REGORAFENIB)

Patent Metadata

Patent number: AU2011244932B9
Jurisdiction: AU
Classification: —
Expires: 2014-06-12
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Pharmaceuticals Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.